Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Conditions:   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy;   Platinum Sensitive Intervention:   Drug: Olaparib 300mg tablets Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials